AMR Action Fund, Illumina Ventures, and Omnimed Capital led a $43m Series D financing round in Pattern Bioscience.

AMR Action Fund, a venture capital fund, Illumina Ventures, an independently-managed, healthcare-focused venture firm, and Omnimed Capital, an investment firm, led a $43m Series D financing round in Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections. “This financing underscores the strong confidence in Pattern’s approach and momentum as we advance into clinical validation. We have aligned with the FDA on our analytical and clinical validation studies, and we feel the urgency to deliver faster treatment guidance to critically ill patients who cannot afford to wait days for effective therapy,” Carey-Ann Burnham, PhD, Pattern Bioscience Chief Executive Officer.